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Available online 25 March 2008Galectin-3 (Gal-3) is a pleiotropic β-galactoside-binding protein expressed at relatively high levels in human
neoplasms. Its carbohydrate recognition domain (CRD) contains a hydrophobic pocket that can accommodate
the farnesyl moiety of K-Ras. Binding of K-Ras to Gal-3 stabilizes K-Ras in its active (GTP-bound) state. Gal-3,
which does not interact with N-Ras, was nevertheless shown to reduce N-Ras-GTP in BT-549 cells by an
unknown mechanism that we explored here. First, comparative analysis of various cancer cell lines
(glioblastomas, breast cancer cells and ovarian carcinomas) showed a positive correlation between lowN-Ras-
GTP/high K-Ras-GTP phenotype and Gal-3 expression levels. Next we found that epidermal growth factor-
stimulated GTP loading of N-Ras, but not of K-Ras, is blocked in cells expressing high levels of Gal-3. Activation
of Ras guanine nucleotide releasing proteins (RasGRPs) by phorbol 12-myristate 13-acetate (PMA) or
downregulation of Gal-3 by Gal-3 shRNA increased the levels of N-Ras-GTP in Gal-3 expressing cells. We
further show that the N-terminal domain of Gal-3 interacts with and inhibits RasGRP4-mediated GTP loading
on N-Ras and H-Ras proteins. Growth of BT-549 cells stably expressing the Gal-3 N-terminal domain was
strongly attenuated. Overall, these experiments demonstrate a new control mechanism of Ras activation in
cancer cells whereby the Gal-3 N-terminal domain inhibits activation of N-Ras and H-Ras proteins.
© 2008 Elsevier B.V. All rights reserved.Keywords:
Ras
Galectin-3
RasGRP4
Cancer1. Introduction
Ras proteins act as binary switches, alternating between GDP-
bound (inactive) and GTP-bound (active) states. Ras is activated by
speciﬁc guanine nucleotide-exchange factors (RasGEFs) including SOS,
RasGRFs and RasGRPs, and is inactivated by speciﬁc Ras GTPase-
activating proteins (RasGAPs) [1–3]. Ras-GTP activates a multitude of
effectors, which trigger a diversity of intracellular signaling networks
that regulate cellular behavior [4–6] Regulation of Ras signaling is
complex and appears to involve combinations of extracellular-signal-
regulated activation of Ras by RasGEFs at the plasma membrane and
endomembranes [7,8] and interactions of Ras with escort proteins,
including galectin-1 (Gal-1) [9–11] and galectin-3 (Gal-3) [12,13],
which were originally discovered as β-galactoside-binding proteins.
Gal-3 [12,14,15] and K-Ras [4,6,15,16] are critical participants in the
regulation of cell growth, differentiation,migration, and survival. Some
of these common regulatory processes appear to be associated with
the rather selective binding of Gal-3 to the activated form of K-Ras
[12,13], the most frequently mutated Ras isoform of the three
prominent H-, N- and K-Ras proteins [16,17]. Gal-3 is unique among
the galectins in possessing, besides the carbohydrate recognition
domain (CRD), a long proline- and glycine-rich NH2-terminal domain
[18–23]. Gal-3,which is highly expressed in humanneoplasms [14], is a+1 972 3 640 7643.
l rights reserved.pleiotropic protein with activities mediated by sugar–protein interac-
tions through the binding of Gal-3 to extracellular β-galactosides [20–
23]. Other activities of Gal-3 appear to involve sugar-independent
interactions with intracellular proteins such as β-catenin [15], synexin
[24], and K-Ras [12,13]. Interaction of K-Ras with Gal-3 and of H-Ras
with Gal-1 [9–11,13], which depend on the farnesyl group of Ras,
prolongs the Ras signal. Structural modeling has identiﬁed highly
homologous putative farnesyl-binding pockets in Gal-3 [25] and in
Gal-1 [11,25], residing between the two β-sheet layers of their
respective CRDs. H-Ras-GTP/Gal-1 complexes [9–11] and K-Ras/Gal-3
complexes [12,13] appear to acquire a conformation that allows
prolongation of the Ras signal by reducing the efﬁciency of p120Ras-
GAP-facilitated GTP hydrolysis by each of these Ras isoforms [13].
Consistent with the above ﬁndings, we recently showed that stable
expression of Gal-3 in human breast cancer cells (BT-549/Gal-3)
coincides with a marked increase in K-Ras-GTP [12] and that speciﬁc
inhibitors for Ras or MEK inhibit Gal-3-mediated resistance to
apoptosis as well as anchorage-independent growth functions [12].
Thus, Gal-3 appears to confer on BT-549 human breast carcinoma cells
several oncogenic functions by binding to wild-type active K-Ras.
Interestingly, the increase in K-Ras-GTP in BT-549/Gal-3 cells is
coupled with a loss of N-Ras-GTP [12]. It was not clear, however, how
Gal-3, which does not interact with N-Ras, would affect activation of
this Ras isoform. In the present study we describe a new control
mechanism of Ras activation whereby Gal-3 inhibits RasGRP4 activity
and thus blocks the RasGRP4-mediated GTP loading of N-Ras and H-
Ras. Two separable domains of Gal-3 appear to regulate Ras activity.
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interacts with K-Ras and stabilizes its GTP-bound state [12,13,25],
whereas the N-terminal domain (residues 1–42) interacts with and
inhibits RasGRP4 activity, thereby inhibiting GTP loading of N-Ras or
H-Ras or both.
2. Materials and methods
2.1. Plasmids and drugs
pEGFP-C3-K-Ras, pEGFP-C3-H-Ras [26], pEGFP-Gal-3, and pEGFP-Gal-3(1–42) [15]
have been described previously. pEGFP-C3-N-Ras was prepared by inserting the entire
coding sequence of humanN-Ras into pEGFP-C3 (Invitrogen, Carlsbad, CA), as previously
described [26]. pBabe-HA-RasGRP4 [27] was a generous gift from Dr. Channing Der,
University of North Carolina at Chapel Hill. pcDNA3-RasGRP2 and pcDNA3-RasGRP3
were a generous gift from Dr. Gary Reuther, University of South Florida, Tampa. The
inhibitors GF109203X, Go6976, SB203580, UO126, and SP600125were fromCalbiochem
(San Diego, CA). Phorbol 12-myristate 13-acetate (PMA), W12, and W13 were obtained
from Sigma-Aldrich, Rehovot, Israel. W12 and W13 were dissolved in ethanol; all other
reagentswere dissolved inDMSO. Ethanol andDMSOwere thus used as vehicle controls.
2.2. Cell culture and transfection
The human breast cancer cell lines BT-549, BT-549 stably expressing Gal-3 (BT-549/
Gal-3) [12], rat intestinal epithelial cells stably expressing the empty vector (RIE-1), and
RIE-1 cells stably expressing the constitutively active H-Ras(Q61L) or K-Ras(G12V)
mutants [28], human embryonic kidney (HEK) 293 cells [13], and baby hamster kidney
(BHK) cells [25] have been previously described. BT-549 cells stably expressing GFP-K-
Ras(G12V) were established by transfection of the cells with pEGFP-K-Ras(G12V)
plasmid and selection in the presence of G418 (800 μg/ml). Several clones of BT-549
cells expressing GFP-K-Ras(G12V) were selected (BT-549/GFP-K-Ras(G12V) cells) and
maintained in complete DMEM containing G418 (400 μg/ml). Glioblastoma (U251,
U373, U87, and 20/20), breast cancer cell lines (MCF7, SKBR3, and MDA-MB-435) and
ovarian carcinoma (CP200, 2780A, and Ovcar3) were purchased from ATCC (Manassas,
VA). Unless otherwise indicated, cells were plated at a density of 1×106 cells per 10-cm
plate and grown at 37 °C in 10 ml of DMEM (or RPMI for Ovcar3 and MDA-MB-435 cell
lines) containing 10% fetal calf serum, 100 µg/ml streptomycin, and 100 U/ml penicillin
in a humidiﬁed atmosphere of 95% air/5% CO2. Cells were cotransfected (calcium
phosphate method) with a total amount of 6 µg of plasmid DNA using the indicated
plasmids and the appropriate empty vector controls. The cells were transfected with
plasmid DNA coding for GFP-Gal-3 (3 µg), GFP-H-Ras (0. 25 µg), GFP-K-Ras (2.0 µg), GFP-
N-Ras (0.5 µg), HA-tagged RasGRP4, RasGRP2 (3 µg), RasGRP3 (3 µg), GFP-tagged-Gal-3
(3 µg), and GFP-tagged Gal-3 N-terminus(1–42) (0.1 µg). The quantities of plasmid DNAs
coding for the Ras isoforms were chosen to obtain equal levels of Ras expression. Cells
were lysed 48 h after transfection in lysis buffers, as described [10].
2.3. Infections and shRNAs
Viruses were produced by transient triple-transfections of HEK 293 cells using 6 μg
retroviral vectors (Open-Biosystems) encoding for speciﬁc shRNA against Gal-3
(V2HS_133962 or V2HS_133963) or RasGRP4 (V2HS_118244 or V2HS_227242) in
combination with 3 μg pMD2G and 3 μg pCGP encoding the retroviral envelope and the
Gag and Pol proteins, respectively. As a control, we used 6 μg of no-silencing shRNA
(Open-Biosystems, RHS1707) or MSCV-PIG encoding GFP. Viruses were collected 48 h
after transfection. Two milliliters of viral supernatant containing 8 μg/ml polybrene
(H9268; Sigma)was used for infections using very low density cultured cells as indicated.
Infected cells were allowed to recover and used at least 72 h after infections for Western
blotting, Ras-GTP pull-down assay or cell proliferation assays as described below.
2.4. Western immunoblotting
Cells were washed with phosphate-buffered saline (PBS) and lysed with lysis buffer
A (50 mM Tris–HCl, pH 7.6, 20 mMMgCl2, 200 mM NaCl, 0.5% Igepal® CA-630 (Sigma),
1 mM DTT, and antiproteases) [10]. Lysates were then subjected to polyacrylamide gel
electrophoresis (PAGE) in the presence of sodium dodecyl sulfate (SDS), followed by
immunoblotting with one of the following antibodies (Abs): 1:2500 pan-Ras Ab; 1:20
anti-K-Ras Ab; 1:20 anti-N-Ras Ab; 1:1000 anti-tubulin Ab; 1:500 anti-Gal-3 Ab;
1:1000 anti-green ﬂuorescent protein (GFP) Ab; 1:500 anti-hemagglutinin (HA) Ab;
1:10,000 anti-phospho-ERK Ab; 1:1000 anti-phospho-JNK Ab; 1:1000 anti-phospho-
P38 Ab; 1:2000 anti-ERK Ab; 1:1000 anti-JNK, or 1:1000 anti-P38 Ab. Immunoblots
were then exposed to 1:5000 peroxidase-goat anti-mouse IgG, 1:5000 peroxidase-goat
anti-rabbit IgG, or 1:5000 peroxidase-goat anti-rat IgG, and protein bands were
visualized using an enhanced chemiluminescence (ECL) kit (Amersham Pharmacia
Biotech, Arlington Heights, IL) and quantiﬁed by densitometry with Image Master VDS-
CL (Amersham) using TINA 2.0 software (Raytest, Isotopenmessgerate, GmbH). Mouse
anti-pan-Ras Ab (Ab-3) was from Calbiochem; isoform-speciﬁc mouse anti-Ras Abs,
mouse anti-phospho-ERK Ab, and mouse anti-tubulin Ab (AK-15) were from Sigma-
Aldrich. Mouse anti-GFP Ab, rabbit anti-phospho-JNK Ab, rabbit anti-JNK Ab, and rabbit
anti-P38 Ab were from Santa Cruz Biotechnology (Santa Cruz, CA). Peroxidase-goatanti-mouse IgG, peroxidase-goat anti-rat IgG, and peroxidase-goat anti-rabbit IgG were
from Jackson ImmunoResearch Laboratories (West Grove, PA). Anti RasGRP4 Ab were
from Abnova (Taiwan).
2.5. Co-immunoprecipitation and Ras-GTP assays
Cell lysates containing 5 mg or 1 mg of proteins in the lysis buffer described above
were prepared for co-immunoprecipitation assay or for assay of the Ras-binding
domain of Raf-1 (RBD), respectively. For the latter assay the concentration of Igepal®
CA-630was reduced to 0.1%. For immunoprecipitation, protein (5mg, adjusted to a total
volume of 1 ml) was incubated for 4 h at 4 °C with 20 µl of mouse anti-HA Ab or of
mouse anti-GFP Ab together with 50 µl of sheep anti-mouse iron beads (Dynal Biotech,
Los Angeles, CA). The beads were then collected using a magnetic ﬁeld, washed three
times with 1 ml of lysis buffer, and the proteins were subjected to SDS-PAGE and
Western immunoblotting with either 1:500 anti-HA Ab or 1:1000 anti-GFPAb and then
with 1:5000 peroxidase-goat anti-mouse IgG (Jackson ImmunoResearch). Lysates
containing 1 mg protein were used for determination of Ras-GTP by the glutathione S-
transferase (GST)-RBD pull-down assay as previously described [10], followed by
Western immunoblotting with Ras-isoform-speciﬁc Abs as described above.
2.6. EGF and PMA stimulation and PKC inhibition
Starting 24 h after transfection of HEK293 cells, the cells were starved of serum for
16 h and then stimulated with 100 ng/ml epidermal growth factor (EGF) for the
indicated time periods. The cells were then lysed and subjected to determination of
Ras-GTP by the GST-RBD pull-down assay, as described above. In experiments where
PMA and phosphokinase C (PKC) inhibitors were used, the PKC inhibitors (3 μM GF or
1 μM Go) or vehicles were added for 20 min, and this was followed by the addition of
40 nM PMA for 30 min. The cells were then lysed and subjected to Western blotting or
to RBD pull-down assay as described above.
2.7. Fluorescence confocal microscopy
BHK cells (1×105 cells per well in six-well plates) were plated on glass cover slips
and then cotransfected with HA-RasGRP4 and GFP or with HA-RasGRP4 and GFP-Gal-3
(1–42). Forty eight hours after transfection, the cotransfectants were incubated for
10 min with vehicle (control) or with 40 nM PMA. The cells were then ﬁxed in PBS
containing 4% paraformaldehyde, and permeabilized with 0.5% Triton X-100. Samples
were blocked (30 min) with 2% bovine serum albumin and 200 μg/ml goat gamma
globulin. Cells were labeled with anti-HA Ab and then with donkey anti-mouse Cy3-
labeled Ab (Jackson ImmunoResearch). Each incubation was followed by three
extensive washes. Dual ﬂuorescent digital images were collected on a Zeiss LSM 510
confocal microscope ﬁtted with ﬂuorescein and rhodamine ﬁlters. The extent of HA-
RasGRP4 translocation to the cell membrane was quantiﬁed by blinded screening of the
images and scoring of 15–30 cells from each cotransfection for the presence or absence
of Cy3 labeling of the plasma membrane. Data represent the percentage of cells with
HA-RasGRP4 labeling of the plasma membrane in each treatment.
3. Results
3.1. Levels of N-Ras-GTP in Gal-3 expressing cells are not dependent on K-
Ras–Gal-3 interactions
Early studies showed that Gal-3 interactswith active K-Ras, reducing
the p120 RasGAP-mediated GTP hydrolysis by K-Ras-GTP, but does not
interact with N-Ras or with H-Ras [13]. To determine whether the low
level of N-Ras-GTP observed in BT-549/Gal-3 cells [12] depends
speciﬁcally on the outcome of interactions of Gal-3 with K-Ras [13],
we examined the effect of constitutively active Ras (which is insensitive
to p120RasGAP) onN-Ras-GTP levels. Expression levelswere assayed by
Western immunoblotting with speciﬁc Gal-3 and Ras-isoform-speciﬁc
Abs, and levels of active Ras were determined by the GST-RBD pull-
down assay followed by immunoblottingwith Ras-isoform-speciﬁc Abs
[12]. In line with earlier reports [29] we found that constitutively active
Ras proteins increased the levels of Gal-3 expression. Thus, stable
expression of GFP-tagged K-Ras(G12V) in BT-549 cells (Fig. 1A) or of K-
Ras(G12V) or H-Ras(Q61L) in RIE-1 cells (Fig. 1B) caused a marked
increase in Gal-3. Concomitantly with the increase in Gal-3 there was a
signiﬁcant decrease in N-Ras protein and a marked decrease in N-Ras-
GTP in each of the cell lines that expressed the constitutively active K/H-
Ras proteins (Fig.1A, B). In agreementwithprevious experiments [12,13]
the decrease in N-Ras-GTP (73–87%) was signiﬁcantly higher than the
decrease in N-Ras protein (21–32%), supporting the hypothesis that Gal-
3 might indirectly regulate N-Ras-GTP levels.
Fig. 1. Negative regulation of N-Ras GTP loading by Gal-3 is independent of Gal-3/K-Ras interactions or on K-Ras signals. (A–C) Constitutively active K-Ras and H-Ras upregulate Gal-3
and downregulate N-Ras-GTP in BT-549 and RIE-1 cells. BT-549 and BT-549/GFP-K-Ras(G12V) cells of two distinct clones (C13 and C19) (A) or RIE-1, RIE-1/H-Ras(Q61L), and RIE-1/ K-
Ras(G12V) cells (B) were grown as described in Materials and methods and then lysed. N-Ras-GTP, K-Ras-GTP, and H-Ras-GTP in samples of the cell lysates were determined by the
GST-RBD pull-down assay followed by immunoblotting with Ras-isoform-speciﬁc Abs, as described in Materials and methods. N-Ras, Gal-3, and β-tubulin (loading control) were
determined in samples of the lysates by immunoblotting with anti-N-Ras, anti-Gal-3, and anti-tubulin Abs. The percentages of N-Ras-GTP relative to the total levels of N-Ras (mean
values±SD, n=3) were 64±%, 40±% and 45±%, respectively, in BT-549, BT-549/C3 and BT549/C19 cells and 84±%, 37±% and 22±%, respectively, in RIE-1, RIE-1/H-Ras(Q61L), and RIE-
1/ K-Ras(G12V) cells. In a second set of experiments (C), BT-549/Gal-3 cells were incubated for 24 h with vehicle (Con) or with 30 μM UO126 (U, a MEK inhibitor), 2.5 μM SB203580
(SB, a p38 inhibitor), or 25 μMSP600125 (SP, a JNK inhibitor). Lysates of the cells were then immunoblotted with anti-Gal-3, anti-ERK, anti-phospho-ERK, anti-p38, anti-phospho-p38,
anti-JNK, and anti-phospho-JNK Abs. (D) Gal-3 levels in human cancer cell lines correlate with high K-Ras-GTP and low N-Ras-GTP. The indicated cancer cell lines were grown as
described in Materials and methods, then lysed, and subjected to the determination of Gal-3, K-Ras, and N-Ras by immunoblotting or of K-Ras-GTP and N-Ras-GTP. Typical
immunoblots are shown in the upper panels. Results of the quantitative analysis obtained by densitometry of four separate experiments are shown in the lower panels. Dark bars and
bright bars represent calculated percentage of N-Ras and K-Ras activity, respectively. Data are presented as mean values (±SD) of Ras-GTP/total Ras in percentage.
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mediated GTP hydrolysis by K-Ras [12,13] this may not account for the
observed reciprocal relationships between Gal-3 and N-Ras-GTP. That
is because such relationships are observed in K-Ras(G12V) expressing
cells (Fig. 1A, B) and this mutant is insensitive to p120 RasGAP. Thus,
whether induced by forced Gal-3 expression [12,13] or by constitu-
tively active K/H-Ras, the higher the levels of Gal-3 the lower the
levels of N-Ras and of N-Ras-GTP. We next examined whether the Gal-
3-associated downregulation of N-Ras-GTP might be mediated
indirectly by signals that originate from activated H/K-Ras protein.
Since the PI3-K/Akt and the RalGEF/Ral pathways are strongly
downregulated in BT-549/Gal-3 cells [12], these Ras pathways did
not appear to contribute to the observed downregulation of N-Ras-
GTP. We therefore examined the ability of pharmacological inhibitors
of other prominent Ras effector pathways to restore the low N-Ras-GTP phenotype in BT-549/Gal-3 cells. As shown in Fig. 1C, the low N-
Ras-GTP phenotype could not be reversed by theMEK inhibitor U0126,
the p38 inhibitor SB203580, or the JNK inhibitor SP600125, each of
which was capable of inhibiting its corresponding target. These
ﬁndings suggested that Gal-3 mediates a decrease in N-Ras-GTP by a
mechanism that does not involve H-Ras-GTP or K-Ras-GTP signaling
through ERK, p38, JNK, PI3K and Ral, at least in BT549/Gal-3 cells, and
is independent of its interactions with K-Ras-GTP.
3.2. Levels of Gal-3 expression in human cancer cell lines positively
correlate with N-Ras/K-Ras usage
To substantiate the possibility that Gal-3 can regulate N-Ras/K-Ras-
isoform usage it was necessary to determine the amount of active N-
Ras and active K-Ras without the forced expression of Gal-3 or of
988 R. Shalom-Feuerstein et al. / Biochimica et Biophysica Acta 1783 (2008) 985–993constitutively active Ras isoforms. We therefore examined whether
variations in the amounts of active N-Ras and active K-Ras in human
cancer cell lines correlate with expression of Gal-3. We screened
human cancer cell lines that do not harbor oncogenic Ras. Compara-
tive analysis of four glioblastoma (GBM) cell lines (U373, U251, U87
and 20–20), three ovarian carcinoma cell lines (CP200, 2780A and
Ovcar3), and four breast cancer cell lines (MCF7, SKBR3, MDA-MB-35
and BT-549) yielded, with only few exceptions, a fairly general pattern
of positive correlation between Gal-3 expression and K-Ras- or N-Ras-
isoform usage within each group of cancer cell lines (Fig. 1D); the
larger the amounts of Gal-3, the lower the amounts of N-Ras-GTP (and
of N-Ras) and the higher the amounts of K-Ras-GTP. Because the ratios
of GTP-bound and total K-Ras or total N-Ras showed the same pattern
of correlation (Fig. 1D), these correlations seem to be associated
mainly, but not only, with the basal state of activation of each of the
Ras isoforms, and less with variations in the protein levels.
The relatively low level of expression of N-Ras in Gal-3 expressing
cells did not appear to be themain reason for lack of N-Ras activation in
such cells. This was evident in experiments inwhich BT-549/Gal-3 cells,
RIE-1/H-Ras(Q61L), 20/20 and Ovcar3 cells were stimulated with the
phorbol ester PMAwhich can activate RasGRPs. Stimulation of the cells
with 40 nM PMA (20 min) induced a clear increase in N-Ras-GTP
without an effect on the total levels of N-Ras (Fig. 2A–C). Apparently, the
PMAtreatment causedN-Ras-GTP levels in BT-549/Gal-3 cells to recover
completely reaching levels recorded in the parental cells (Fig. 2A).
3.3. Gal-3 expression blocks EGF-stimulated activation of N-Ras but not
of K-Ras
To further support the conclusion that the effects of Gal-3 on K-Ras
and on N-Ras are separable we examined the time-dependent GTP
loading of N-Ras and K-Ras stimulated by EGF. Using BT-549 cells,
which express low levels of Gal-3 [12], we found that EGF induced a
typical transient increase in N-Ras-GTP that peaked at 5–10 min and
faded within 30 min (Fig. 3A). K-Ras-GTP levels did not increase upon
stimulationwith EGF (Fig. 3A), supporting the importance of Gal-3 for
K-Ras activity in these cells (Fig. 1D) [12]. In BT-549/Gal-3 cells which
express high levels of Gal-3 EGF indeed induced strong activation of K-
Ras, which peaked at 5–10 min and faded within 30 min (Fig. 3B).Fig. 2. PMA, independent of PKC, rescues the low N-Ras-GTP phenotype of Gal-3 expressing c
or 1 μMGo6976 then treated for 30 minwith or without 40 nM PMA, and lysed. (D) In separa
calmodulin inhibitorsW12 orW13 (each 15 μg/ml). The cells were then lysed, and N-Ras-GTP
typical immunoblots. Lower panels: quantitative analysis of the results obtained by densitoLoading of N-Ras-GTP, however, was completely blocked in the EGF-
stimulated BT-549/Gal-3 cells (Fig. 3B). Similar results were obtained
in an analogous experiment performedwith the RIE-1 andwith the H-
Ras- or K-Ras-transformed RIE-1 cell lines. Here too, EGF induced a
time-dependent increase in N-Ras-GTP loading in the RIE-1 cells
whereas the GTP loading of N-Ras in RIE-1/K-Ras(G12V) or in RIE-1/H-
Ras(Q61L) cells was completely blocked (Fig. 3C).
The complete inhibition of GTP loading of N-Ras in the very same
cells in which GTP loading of K-Ras was highly effective (BT-549/Gal-
3) or in cells that constitutively express active H-Ras or K-Ras (RIE-1/
Ras cells), all of which strongly expressed Gal-3, suggested that Gal-3
might inhibit a RasGEF that induces the exchange of GTP for GDP in N-
Ras. Activation of an N-Ras-speciﬁc GAP by Gal-3 could nonetheless
also decrease N-Ras-GTP levels. The observed rescue of the low N-Ras-
GTP phenotype by PMA in Gal-3 expressing cells (Fig. 2) hinted to the
possible involvement of a PMA-sensitive RasGEF.
3.4. Phorbol ester rescues the low N-Ras-GTP phenotype in Gal-3
expressing cells independently of PKC
Three families of RasGEFshavebeendescribed: the SOS family (SOS1
and SOS2), the RasGRF family (RasGRF1and RasGRF2), and the RasGRP
family (RasGRP 1–4) [2,3]. The pharmacological experiments showing
that PMA rescued the low N-Ras-GTP phenotype in Gal-3 expressing
cells (Fig. 2) have pointed to the possible involvement of a RasGRP since
RasGRPs are activated by diacylglycerol (DAG) or by phorbol esters that
bind to their C1 domain [2,3]. We found, nonetheless, that rescue of the
low N-Ras-GTP phenotype in Gal-3-expressing cells by PMA was not
blocked by the PKC inhibitors GF109203X or Go6976 (Fig. 2A–C),
suggesting that the effect was mediated by PMA-induced activation of
RasGRPs, not by PMA-mediated activation of PKCs. This possibility was
supported by the ﬁnding that the PKC inhibitors themselves did not
reduce the high-level N-Ras-GTP phenotype in parental BT-549 and
RIE-1 cells (Fig. 2A, B). Because the activityof RasGRP1andRasGRP3, but
not of RasGRP2 or RasGRP4, depends on PKC [2,3] the effect of PMA
could apparently be mediated by activation of RasGRP2 or RasGRP4.
These experiments, however, did not rule out the possibility that the
low N-Ras-GTP phenotype in Gal-3-expressing cells is also mediated
by Gal-3 inhibition of the activity of SOS1/2 or RasGRFs activity.ells. (A–C) The indicated cells were incubated for 20 minwith or without 3 μM 109203X,
te experiments, BT-549 and RIE-1 cells were incubated for 20 minwith or without Ca2+/
and N-Ras expression in the lysates was determined as described in Fig. 1. Upper panels:
metry (arbitrary units, AU) in three separate experiments (means±SD).
Fig. 3. Gal-3 expression in BT-549 cells or RIE-1/Ras cells blocks EGF-stimulated
activation of N-Ras but not of K-Ras. BT-549 cells (A) or BT-549/Gal-3 cells (B) or RIE-1
and RIE-1/Ras cells (C) were starved of serum for 12 h, then incubated for the indicated
times with 100 ng/ml EGF, and lysed as described in Materials and methods. N-Ras-GTP
and K-Ras-GTP in the cell lysates were determined as described in Fig. 1. Upper panels:
typical immunoblots. Lower panels: quantitative analysis of the results obtained by
densitometry (arbitrary units, AU) in three separate experiments (means±SD).
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downregulate the relatively high levels ofN-Ras-GTP in the parental BT-
549 and RIE-1 cells (Fig. 2D); since the activity of RasGRFs depends on
Ca2+/calmodulin [2,3], this ﬁnding suggests that the high levels of N-
Ras-GTP recorded in these cells are independent of RasGRFs.3.5. Gal-3 inhibits the RasGRP4-mediated increase in N-Ras-GTP
To substantiate the hypothesis that Gal-3 inhibits a RasGRP-
mediated GTP loading of N-Ras, we ﬁrst used HEK293 cells that were
cotransfected with RasGRP2 and a control vector, or with RasGRP2 and
GFP-N-Ras or GFP-H-Ras. After 48 h no RasGRP2-mediated increase in
GFP-N-Ras or GFP-H-Ras was detectable (not shown), possibly because
of the lowRas-exchange activity of RasGRP2, as reportedpreviously [27].
We then examined the activity of GRP4. Thiswas done by cotransfecting
HEK293 cells with GFP-N-Ras and a control vector, or with GFP-N-Ras,
RasGRP4 and empty vector, or with GFP-N-Ras, RasGRP4 and Gal-3. On
examining GFP-N-Ras-GTP levels 48 h after the transfections, we found
that RasGRP4 had inducedGTP loadingof GFP-N-Ras, as indicated by the
signiﬁcantly higher levels of GFP-N-Ras-GTP recorded in theGFP-N-Ras/
RasGRP4 cotransfectants than in the GFP-N-Ras/empty vector cotrans-
fectants (Fig. 4A). GFP-N-Ras-GTP levels recorded in the GFP-N-Ras/
RasGRP4/Gal-3 cotransfectants, however, were much lower than those
recorded in the GFP-N-Ras/RasGRP4 cotransfectants (Fig. 4A). These
results showed that Gal-3 can inhibit the RasGRP4-mediated GTP
loading of GFP-N-Ras, and suggested that Gal-3 might interact directly
with RasGRP4 to block its guanine nucleotide-exchange activity.
Separate co-immunoprecipitation experiments using HEK293 cells
cotransfected with Gal-3 and HA-RasGRP4 conﬁrmed that Gal-3
interacts with HA-RasGRP4 (Fig. 4B).
In view of previous ﬁndings that H-Ras serves as a substrate for
RasGRP4 [27], itwas reasonable to assume that Gal-3would also inhibit
RasGRP4-mediatedH-Ras-GTP loading. ExperimentswithHEK293 cells
cotransfected with GFP-H-Ras and HA-RasGRP4 conﬁrmed the earlier
ﬁndings; HA-RasGRP4 induced an increase in GFP-H-Ras-GTP (Fig. 4A).
Consistent with our assumption, Gal-3 indeed inhibited the HA-
RasGRP4-mediated GTP loading of GFP-H-Ras (Fig. 4A). Similar
experiments performed with GFP-K-Ras/HA-RasGRP4 cotransfectants
showed that HA-RasGRP4 induced only a small, non-signiﬁcant
increase in GFP-K-Ras-GTP (Fig. 4A). Thus, K-Ras appears to be a poor
substrate for RasGRP4. The observed rank order of potency of HA-
RasGRP4-induced GTP loading of the various Ras substrates was clearly
GFP-H-Ras=GFP-N-RasNNNGFP-K-Ras (Fig. 4A). Taken together, these
experiments showed that H-Ras andN-Ras are preferable substrates for
RasGRP4,which is for itself inhibited byGal-3. Theseobservations are in
line with our pharmacological data suggesting that selective inhibition
of the DAG-dependent/PKC-independent exchange factor RasGRP4 by
Gal-3, not inhibition of the PKC-dependent RasGRP1/3, contributes to
the lack of N-Ras activation in cells that express high levels of Gal-3.
Consistent with this conclusionwe found that RasGRP4 is expressed in
Ovcar3 and in 20–20 GBM cells which exhibit relatively high levels of
Gal-3 and low levels of N-Ras-GTP (Fig. 4D).
Several lines of evidence supported this conclusion. First, down-
regulationofGal-3 by twodistinctGal-3 shRNAs in20–20GBMcellswere
accompanied by an increase in the levels of N-Ras-GTP (Fig. 4C). Non-
silencing shRNA had no effect on Gal-3 or on N-Ras-GTP levels (Fig. 4C).
Similar results were obtained in RIE-1/H-Ras(Q61L) (Fig. 4C). Second, we
found that downregulation of RasGRP4 by two distinct RasGRP4 shRNAs
in BT-549 caused a decrease inN-Ras-GTP (Fig. 4D). Non-silencing shRNA
had no effect on RasGRP4 or N-Ras-GTP levels (Fig. 4D). Third, we found
that activity of the PKC-dependent RasGRP3, which itself induced strong
activation of GFP-N-Ras in GFP-N-Ras/RasGRP3 HEK293 cotransfected
cells, was not inhibited by Gal-3 expression (Fig. 4E).
3.6. The N-terminal domain of Gal-3 inhibits RasGRP4-mediated increase
in GFP-N-Ras-GTP
Gal-3 does not interact with N-Ras but interacts with K-Ras-GTP
through the C-terminal CRD domain of Gal-3 which is separate to the
N-terminal 1–42 region. We thus wondered whether the observed
RasGRP4-mediated N-Ras GTP loading might involve interaction of
RasGRP4 with the N-terminal domain of Gal-3. To test this hypothesis
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(GFP-Gal-3(1–42)) on RasGRP4-mediated GTP loading of N-Ras. In
these experiments HEK293 cells were cotransfected with N-Ras, HA-
RasGRP4, and GFP-Gal-3(1–42) or GFP, and the levels of N-Ras-GTP in
the cotransfectants were then determined. The results showed that N-
Ras-GTP was strongly reduced in the GFP-N-Ras/HA-RasGRP4/GFP-Gal-3(1–42) cotransfectants (Fig. 4A). Similar results were obtained
when we examined HA-GRP4-mediated H-Ras-GTP loading in the
presence of GFP-Gal-3(1–42) (Fig. 4A). GFP-Gal-3(1–42) did not inhibit
the RasGRP3-induced GTP loading of N-Ras (Fig. 4D), suggesting that
the effect was speciﬁc to RasGRP4. Co-immunoprecipitation experi-
ments using GFP-Gal-3(1–42)/HA-RasGRP4 cotransfectants conﬁrmed
that that GFP-Gal-3(1–42) interacts with HA-RasGRP4 (Fig. 4B). It thus
appears that the N-terminal domain of Gal-3 can bind to RasGRP4 and
that this domain is sufﬁcient for inhibition of RasGRP4 activity.
Previous experiments have shown that PMA enhances RasGRP4
activation and its translocation to the membrane [27]. Thus, the
observed inhibition of RasGRP4 activity by Gal-3 suggested that Gal-3
might actually inhibit its membrane translocation. This possibility was
examined by ﬂuorescence confocal microscopy in BHK cells that were
transfectedwith HA-GRP4 and GFP or cotransfected with HA-RasGRP4
and GFP-Gal-3(1–42), and then stimulated with PMA (40 nM,10 min).
HA-RasGRP4 was labeled with anti-HA mouse Ab and then with
donkey anti-mouse Cy3-labeled Ab, and dual ﬂorescent confocal
images were collected (green, GFP; red HA-RasGRP4). Typical images
demonstrate that PMA induced strong translocation of RasGRP4 to the
plasmamembrane (Fig. 5), consistent with reported observations [27].
The PMA-induced translocation of RasGRP4 was strongly attenuated
by GFP-Gal-3(1–42) (Fig. 5); whereas 79% of the HA-RasGRP4-
transfected cells exhibited PMA-induced translocation ofHA-RasGRP4,
only 33% exhibited PMA-induced translocation in the HA-RasGRP4/
GFP-Gal-3(1–42) cotransfectants.
3.7. Gal-3(1–42) reverses the transformed phenotype of BT-549 cells
The marked inhibition of RasGRP4-mediated N-Ras GTP loading by
Gal-3(1–42) prompted us to examine whether Gal-3(1–42) can affect
the transformed phenotype of BT-549 cells. We employed two distinct
clones of BT-549 cells stably expressing GFP-Gal-3(1-42) and found, as
expected, that GFP-Gal-3(1–42) caused a marked reduction in theFig. 4. Gal-3 or its N-terminal domain inhibits the RasGRP4-mediated increase in GFP-
N-Ras-GTP and GFP-H-Ras-GTP. (A) HEK293 cells were cotransfected with the following
combinations of plasmids as described in Materials and methods: GFP-N-Ras or GFP-H-
Ras or GFP-K-Ras and empty vectors; GFP-N-Ras/HA-RasGRP4, GFP-H-Ras/HA-RasGRP4,
GFP-K-Ras/HA-RasGRP4; GFP-N-Ras/HA-RasGRP4/GFP-Gal-3, GFP-H-Ras/HA-RasGRP4/
GFP-Gal-3; GFP-N-Ras/HA-RasGRP4/GFP-Gal-3(1–42), and GFP-H-Ras/HA-RasGRP4/
GFP-Gal-3(1–42). The cells were lysed 48 h after transfection and the lysates were
subjected to N-Ras-GTP determination as described in Fig. 1 and to immunoblotting
with anti-pan-Ras (Ras), anti-HA (RasGRP4), anti-GFP (Gal-3, Gal-3(1–42)) or anti β-
tubulin (loading control) Abs. (B) Co-immunoprecipitation of HA-RasGRP4 and GFP-
Gal-3 (left panels) or of HA-RasGRP4 and GFP-Gal-3(1–42) (right panels). HEK293 cells
were cotransfected with HA-RasGRP4/GFP-Gal-3 or with HA-RasGRP4/GFP-Gal-3(1–42)
and lysed 48 h later. The cell lysates were subjected to immunoprecipitation (IP) with
anti-GFP Ab (+) or with naive Ab (−) followed by immunoblotting (IB) with anti-HA Ab
(RasGRP4) or anti-GFP Ab (Gal-3), or to immunoprecipitation with anti-HA Ab (+) or
naive Ab (−) followed by immunoblotting with anti-GFP Ab or anti-HA Ab, as described
in Materials and methods. Typical blots are shown. Similar results were obtained in two
additional experiments. (C) The impact of Gal-3 shRNA on N-Ras-GTP levels in cancer
cells. Glioblastoma 20–20 cells were infected with retroviruses containing two distinct
shRNA sequences against Gal-3 (left panels, sh1+ or sh2+). Viruses containing non-
silencing shRNA sequences (sh−) or GFP were used as controls. Results of a similar
experiment performedwith RIE-1/H-Ras(Q61L) are shown in the left panels. Cell lysates
were prepared 72 h after the infection and the levels of Gal-3, N-Ras and N-Ras-GTP
were determined as described in Fig. 1. Immunoblots of one of the two experiments
with similar results are shown. D. Upper panels — BT-549 cells were infected with
retroviruses containing two distinct shRNA sequences against RasGRP4 (sh1+ or sh2+)
or non-silencing shRNA sequences (sh−). N-Ras, N-Ras-GTP and RasGRP4 were
determined as described in Fig. 1. Immunoblots of one of the two experiments with
similar results are shown. Lower panel — Cancer cell line expresses RasGRP. Lysates of
Ovcar3 and 20–20 cell lines were immunoblotted with anti RasGRP4 Ab. Mast cell lysate
(mast) served as a control. (E) RasGRP3-induced GTP loading of GFP-N-Ras is not
inhibited by Gal-3 or by Gal-3(1–42). HEK293 cells were cotransfected with GFP-N-Ras/
empty vectors, GFP-N-Ras/RasGRP3, GFP-N-Ras/RasGRP3/GFP-Gal-3, or GFP-N-Ras/
RasGRP3/GFP-Gal-3(1–42), and lysed 48 h later. N-Ras-GTP in the cell lysates was
determined as described in Fig. 1. Immunoblots of one of the two experiments with
similar results are shown.
Fig. 5. Gal-3(1–42) inhibits PMA-induced translocation of RasGRP4 to the plasma
membrane. BHK cells were plated on glass cover slips and then cotransfected with HA-
RasGRP4 and GFP or with HA-RasGRP4 and GFP-Gal-3(1–42). The cotransfectants were
incubated 48 h after transfection with vehicle control (Con) or with 40 nM PMA
(10min), then ﬁxed and labeledwithmouse anti-HA Ab followed by donkey anti-mouse
Cy3-labeled Ab. Dual ﬂuorescent confocal images (GFP and Cy3) were then collected. (A)
Typical Cy3 (red), GFP (green), and merged images demonstrating the cytoplasmic
localization of HA-RasGRP4, the PMA-induced translocation of HA-RasGRP4 to the
plasma membrane, and the attenuated translocation forced by GFP-Gal-3(1–42). (B)
Quantiﬁcation of the results. Data represent the percentage of cells with plasma
membrane localized HA-RasGRP4 (means±SD, four separate experiments) calculated as
described in Materials and methods.
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morphology was observed (Fig. 6A) accompanied by a marked
reduction in growth rate (60% reduction, Fig. 6B).
We also examined sensitivity of BT-549/GFP-Gal-3(1–42) to
cytotoxic drugs in comparison with the sensitivity of the parental
BT-549 to such drugs. The cells were exposed to 10 μMadriamycine for
24 h or to 500 nM staurosporine for 8 h then subjected to FACS
analysis. In line with previous experiments [12], adriamycine and
staurosporine induced an increase in the sub-G1 population of cells
(indicative of apoptotic cell death) in BT-549 cells (Fig. 6C). The
increase in sub-G1 population observed in all BT-549/GFP-Gal-3(1–42)
cell lines was clearly higher than that observed in BT-549 cells (Fig. 6C)
suggesting that GFP-Gal-3(1–42) had rendered the cells more sensi-
tive to apoptosis, namely had partially reversed their transformed
phenotype.
4. Discussion
The results presented here point to a new control mechanism
showing that Gal-3 protein can regulate the RasGRP4-mediated GTP
loading of N-Ras or H-Ras in cancer cells. It appears that Gal-3 does notaffect RasGRFs and SOS1/2, although this possibility has not yet been
unequivocally excluded. Whether or not Gal-3 can affect the activity of
GRP2 might be less important for N- and H-Ras, because this exchange
factor appears to actmorepotentlyas anexchange factorof Rap1 thanof
Ras proteins [3,27]. On the basis of our results and of earlier studies
[12,13,25], we propose a model that can explain the shift from N-Ras to
K-Ras usage in cells expressing high levels of Gal-3 (Fig. 6D). In our
model, two separable domains of Gal-3 act independently on K-Ras and
on RasGRP4 to promote, respectively, accumulation of active K-Ras
[12,13] and inhibition of N-Ras or H-Ras activation. One domain is the
CRD, which can accommodate the farnesyl moiety of K-Ras [25] and
strengthen the direct binding of Gal-3 to K-Ras-GTP [13]. The other
domain is the N-terminal tail of Gal-3, which interacts with RasGRP4
and inhibits its activity. The model can explain the Gal-3-associated
high K-Ras-GTP/low N-Ras-GTP phenotype observed in BT-549/Gal-3
cells and in human cancer cell lines such as GBM, breast cancer cells,
and ovarian carcinomas. Consistent with the model, we found that
downregulation of Gal-3 by Gal-3 shRNA, or that phorbol 12-myristate
13-acetate (PMA) activating Ras guanine nucleotide releasing proteins
(RasGRPs) independently of protein kinase C, both, increased N-Ras-
GTP levels in Gal-3 expressing cells. In accordance downregulation of
RasGRP4 by RasGRP4 shRNA reduced the levels of N-Ras-GTP. Because
PMA andDAG both enhance activation of RasGRP4 by binding to the C1
domain of RasGRP4 [27], it is possible that the N-terminal tail of Gal-3
interacts with the C1 domain. Our results thus assign to the N-terminal
domain of Gal-3, whose signiﬁcance in cell transformation has been
well documented [19,30], a novel regulatory function.
It appears then that cancer cells expressing high levels of Gal-3
with their chronically active K-Ras are phenocopies of the K-Ras
mutation, which is the most common oncogenic Ras mutation in
human tumors [16,17]. This emphasizes the important contribution of
K-Ras [16,17] and of Gal-3 [14] to humanmalignancies. Nonetheless, it
is not unlikely that activated N-Ras or H-Ras would predominate in
cancer cells that do not harbor oncogenic K-Ras, or in cells that express
low levels of Gal-3, or both. In such cells RasGRP4, which would be
free of Gal-3 inhibition, might be a critical transforming factor.
Consistent with this possibility we showed that reducing RasGRP4
activity in BT-549 by Gal-3(1–42) partially reversed their transformed
phenotype (Fig. 6). Earlier experiments indeed demonstrated that
RasGRP4 and RasGRP1 are potent inducers of cell transformation,
whereas RasGRP2 and RasGRP3 are weak inducers [2,3]. An important
question that remains to be answered is whether or not the speciﬁc
pattern of Ras-isoform usage has a distinctive impact on the biology of
cancer cells, and if so, what its outcome is. The case of BT-549/Gal-3
cells suggests that high levels of Gal-3 and K-Ras-GTP with
concomitantly low levels of N-Ras-GTP promote a more aggressive
phenotype. For example, BT-549/Gal-3 cells are more resistant to
apoptosis than BT-549 cells, and they form tumors in nude mice
whereas BT-549 cells do not. Similarly, thyroid tumors that express
high Gal-3 levels are far more aggressive and invasive than those
expressing low levels of Gal-3 [14,31]. Other studies have shown that
K-Ras is a more potent inducer of cell migration than H-Ras or N-Ras
[32], while yet others have demonstrated that oncogenic H-Ras is
more potent than oncogenic K-Ras or N-Ras in inducing cell
proliferation and focus formation [33]. The later, however, refers to
mouse ﬁbroblasts that depend on Raf-Mek-Erk pathway andmay then
not be relevant to human carcinomas. Nonetheless, it possible that
signals originating from active K-Ras contribute more critically to
cancer cell migration and invasion, whereas those that originate from
H-Ras or N-Ras might be more important for cell-cycle progression.
It is more reasonable to assume that the impact of Ras-isoform
usage would be determined not only by the active Ras protein but also
by the speciﬁc cellular context of the given type of cancer or normal
cell and by the cellular localities of the Ras isoform and the RasGEFs.
Clearly, factors other than Gal-3 can determine Ras-isoform activation
and signaling. It was shown, for example, that activated K-Ras can
Fig. 6. Gal-3(1–42) or RasGRP4 shRNA partially reverse the transformed phenotype of BT-549. BT-549 cells and BT-549 cells stably expressing GFP-Gal-3(1–42) or RasGRP4 shRNA or
non-silencing RNAwere incubated and subjected either to the determination of the levels of N-Ras and N-Ras-GTP (A) or toMTT assays (B) as described inMaterials andmethods. (A)
Typical immunoblots of two clones of GFP-Gal-3(1–42) expressing cells (C9, C11) are shown in the left panel and typical images of the cells are shown in the right panel. (B) The
apparent number of viable GFP-Gal-3(1–42) (left) and RasGRP4 shRNA (right) expressing cells grown for the indicated periods of time. (C) GFP-Gal-3(1–42) increases sensitivity to
cytotoxic drug-induced apoptosis. Apoptosis was induced in BT-549, and in BT-549 cells stably expressingGFP-Gal-3(1–42) (clones C9 and C11) by 10 µM adriamycine (ADR) for 24 h or
by 500 nM staurosporine for 8 h. The cells were subjected to FACS analysis as described inMaterials andmethods. Results of a typical analysis are shown for control (Con), adriamycine
and staurosporine treated cells. The percentage of cells in sub-G1 is denoted in each panel. Similar results were obtained in two additional experiments. (D) Proposed model of two
separable Gal-3 domains that regulate Ras-isoform usage in cancer cells. The model depicts RasGRP4-mediated exchange of GTP for GDP on H/N-Ras proteins, a procedure that is
blocked by the direct interaction of the N-terminal domain of Gal-3with RasGRP4 (presentﬁndings). Themodel also depicts, as an example, SOS-mediated exchange of GTP for GDP on
K-Ras. Once loaded with GTP, K-Ras interacts with the CRD domain of Gal-3, and this interaction, as shown previously [13], reduces the hydrolysis of p120RasGAP-mediated GTP by K-
Ras. Accordingly, Gal-3 expression causes a low H/N-Ras-GTP and high K-Ras-GTP phenotype, as observed in cancer cells expressing high levels of Gal-3.
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increase in interactions between N-Ras and gelsolin [34].
Other studies have shown that Gal-1 increases H-Ras activation
and signaling to ERK at the expense of PI3K [10] and RalGEF [25], and
enhances H-Ras transformation [9]. Perhaps even more intriguing are
the observations that under certain circumstances oncogenic K-Ras
can act as amitochondrial pro-apoptotic factor [35], while under other
conditions K-Ras(G12V) can act as a survival factor [28]. Also, other
studies have shown that RasGRP1 and RasGRP3 can speciﬁcally
activate H-Ras in the Golgi [2,36]. Finally, it is interesting to point out
that expression of mouse and rat RasGRP4 proteins is restricted to
mast cells [37] where RasGRP4 functions as an H-Ras exchange factorinvolved in airway reactivity and allergic inﬂammation [37]. In this
context other studies have shown that mast cells from Gal-3 deﬁcient
mice exhibit impaired histamine and Il-4 release and reduced levels of
JNK [38]. Our results suggest that the levels of expression of Gal-3 may
determine Ras isform usage in mast cells.
In conclusion, this study presents a novel dual-control mechanism
of Ras proteins whereby Gal-3 inhibits RasGRP4-mediated activation
of N/H-Ras through its N-terminal domain and stabilizes K-Ras-GTP
through its CRD domain. Future experiments focusing on the levels of
expression and of Gal-3, and on various RasGEFs and their Ras isoform
GTP-loading activities, will shed more light on the importance of Ras-
isoform usage for the survival, migration, and proliferation of cancer
993R. Shalom-Feuerstein et al. / Biochimica et Biophysica Acta 1783 (2008) 985–993cells. Such knowledge should provide guidelines for the design of
speciﬁc and selective Ras inhibitors as potential anti-tumor drugs.
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